Physician profile
Dalton E Rodriguez
NPI 1548537533
$1,333.28
in general payments reported to CMS, 2019-2025
22 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.41 · 2022: $123 · 2023: $631 · 2024: $325 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $186.03 | 2022-2023 | Xarelto |
| Novo Nordisk INC | $162.46 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $156.27 | 2022-2024 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.67 | 2023-2025 | Lifevest |
| Philips North America LLC | $75.25 | 2023-2025 | Ecc Solutions, Mcot |
| Merck Sharp & Dohme LLC | $70.91 | 2022-2023 | Verquvo |
| Amgen INC. | $66.97 | 2023-2024 | Repatha |
| Abiomed | $66.14 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $62.01 | 2023-2024 | Evkeeza, Praluent |
| E.R. Squibb & Sons, L.L.C. | $60.00 | 2021-2023 | Camzyos |
| Pfizer INC. | $52.84 | 2023-2025 | |
| Scpharmaceuticals INC. | $39.13 | 2023-2024 | |
| Daiichi Sankyo INC. | $29.15 | 2024 | Injectafer |
| Boston Scientific Corporation | $28.24 | 2023 | Vigilant X4 Crt-D |
| Altathera Pharmaceuticals LLC | $25.35 | 2022-2024 | Sotalol Hydrochloride |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.31 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.80 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $17.50 | 2024 | |
| Chiesi USA, INC. | $16.93 | 2024 | Kengreal, Cleviprex |
| Kiniksa Pharmaceuticals, LTD. | $15.78 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $13.39 | 2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.15 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalton Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.